STOCK TITAN

RHYTHM PHARMACEUTICALS (RYTM) SEC Filings, Feb 13-19, 2026

RYTM NASDAQ

Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.

Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.

Rhea-AI Summary

Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith reported open-market sales of a total of 7,954 shares of common stock on February 17 and 19, 2026, at prices generally around $100 per share.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. After these sales, Smith directly holds 110,512 shares of Rhythm Pharmaceuticals common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
insider
-
Rhea-AI Summary

Rhythm Pharmaceuticals EVP Yann Mazabraud reported equity award activity involving restricted stock units and common stock. On February 14, 2026, he exercised or converted 10,000 restricted stock units into 10,000 shares of common stock at a price of $0.00 per share, reflecting the non-cash nature of the award.

After these transactions, he directly held 30,000 restricted stock units and 53,155 shares of common stock. Each restricted stock unit represents a right to receive one share of common stock and vests in four 25% installments on February 14, 2026, February 1, 2027, February 1, 2028, and February 1, 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
insider
-
Rhea-AI Summary

RA Capital Management and affiliates reported a sizable passive stake in Pharmaceuticals, Inc. They beneficially owned 6,666,837 shares of common stock, representing 9.99% of the company’s outstanding shares as of December 31, 2025, based on 66,736,056 shares outstanding on October 31, 2025.

The shares are directly held by RA Capital Healthcare Fund, L.P., which has delegated sole voting and investment power to RA Capital Management, L.P. Individuals Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their control of RA Capital, but all reporting persons disclaim beneficial ownership beyond Section 13(d) requirements.

The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, indicating a passive investment intent rather than an activist position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
ownership
Rhea-AI Summary

Shulman Joseph, Chief Technical Officer of Pharmaceuticals, Inc., reported new equity awards. On February 11, 2026, he received 15,000 restricted stock units and stock options for 22,500 shares with a $98.47 exercise price, all held directly.

The restricted stock units vest in four equal 25% installments on February 1 of 2027, 2028, 2029 and 2030 and have no expiration date. The options were granted on February 11, 2026 and vest in 16 substantially equal installments, each after three full months of continued service, until fully exercisable by February 10, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider
-
Rhea-AI Summary

RYTM Pharmaceuticals’ President and CEO David P. Meeker reported equity awards consisting of restricted stock units and stock options. On February 11, 2026, he received 71,900 restricted stock units, each representing the right to receive one share of common stock. These units vest 25% each on February 1, 2027, 2028, 2029 and 2030.

On the same date, he was also granted 107,850 stock options with an exercise price of $98.47 per share. These options vest in 16 substantially equal quarterly installments, based on completing each three full months of successive service after the grant date. Both awards are held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider
-
Rhea-AI Summary

Mazabraud Yann reported acquisition or exercise transactions in this Form 4 filing.

Pharmaceuticals, Inc. executive Yann Mazabraud, EVP and Head of International, reported receiving a grant of 23,350 restricted stock units on February 11, 2026. This was an award of derivative securities at a reported price of $0 per unit, held as direct ownership.

The restricted stock units give a contingent right to receive one share of common stock for each unit. They vest in four equal installments of 25% of the total grant on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030, and have no expiration date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider
Rhea-AI Summary

Rhythm Pharmaceuticals executive Jennifer Kayden Lee received new equity awards tied to her role as EVP, Head of North America. On February 11, 2026, she was granted 21,650 restricted stock units, each representing one share of common stock, and 32,500 stock options with a $98.47 exercise price.

The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029, and 2030 and have no expiration date. The stock options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date. All awards are held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider
-
Rhea-AI Summary

German Christopher Paul reported acquisition or exercise transactions in a Form 4 filing for RYTM. The filing lists transactions totaling 5,215 shares. Following the reported transactions, holdings were 5,215 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider
-
Rhea-AI Summary

Rhythm Pharmaceuticals’ Chief Scientific Officer Alastair Garfield received new equity awards. On February 11, 2026, he was granted 16,650 restricted stock units, each representing one share of common stock, and 25,000 stock options with an exercise price of $98.47 per share.

The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029 and 2030. The options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider
Rhea-AI Summary

Rhythm Pharmaceuticals’ Chief Human Resources Officer Pamela J. Cramer received new equity awards. On February 11, 2026, she was granted 11,650 restricted stock units, each representing one share of common stock. These RSUs vest in four equal 25% installments on February 1 of 2027, 2028, 2029, and 2030.

She was also granted stock options for 17,500 shares of common stock at an exercise price of $98.47 per share. These options vest in 16 substantially equal installments, based on completing each three full months of successive service after the grant date. All awards are held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
insider

FAQ

How many RHYTHM PHARMACEUTICALS (RYTM) SEC filings are available on StockTitan?

StockTitan tracks 138 SEC filings for RHYTHM PHARMACEUTICALS (RYTM), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for RHYTHM PHARMACEUTICALS (RYTM)?

The most recent SEC filing for RHYTHM PHARMACEUTICALS (RYTM) was filed on November 17, 2026.